Dr Brian Slomovitz talks to ecancer at ASCO 2025 about a trial he presented from the ROSELLA trial. This trial is being conducted in collaboration with The GOG Foundation, Inc. (GOG-F), the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG). 

Dr Slomovitz notes that relacorilant plus nab-paclitaxel is the first treatment regimen to demonstrate a PFS and OS benefit in patients with platinum-resistant ovarian cancer compared to a weekly taxane, the most efficacious comparator.

He adds that the data and safety profile position relacorilant plus nab-paclitaxel as a potential new standard for patients with platinum-resistant ovarian cancer, without the need for biomarker selection.